Credibility And Crying Wolf: US FDA Petition Guidance Says Past Practices Can Count Against You
FDA is warning sponsors that a history of generic-delaying tactics may come back to haunt them when the agency considers whether a Citizen Petition is frivolous and potentially anti-competitive. But so will waiting too long to speak up.
You may also be interested in...
New draft guidance says citizen petition abuses will be referred to FTC and publicly called out as attempts to delay ANDA approvals.
An independent review of the US FDA’s food regulatory programs could renew a debate over splitting FDA into two agencies. That could be a distraction for the agency in the coming year – but it could also help keep the medical product review groups out of the political hot seat.
Biotech sponsors understandably discuss accelerated approval as an important consideration in development plans. But the head of the US FDA oncology program has a reminder for them: the pathway is intended to serve patients – not drug companies.